AI’s Approaches to Maternal and Neonatal Health in Low Resource Settings
By Sumona Bose
December 23, 2023
Introduction
A significant challenge faced by hospitals and medical practitioners in low- and middle-income countries is the lack of sufficient healthcare facilities for timely medical diagnosis of chronic and deadly diseases. Maternal and neonatal morbidity due to non-communicable and nutrition-related diseases is a serious public health issue that leads to several deaths every year. Detecting these conditions at their early stages is challenging, putting patients at risk of developing severe conditions over time. However, the advent of Artificial Intelligence (AI) has opened up new possibilities for improving maternal and neonatal health. This article will give an overview on AI’s Approaches to Maternal and Neonatal Health in Low Resource Settings.
AI holds Promise for Maternal and Neonatal Health
AI has emerged as a practical assistive tool in various healthcare sectors, but its application in maternal and neonatal health is still in its nascent stages. One example of how AI can be used in low-resource settings is in maternal health and diagnostics services. In these settings, access to proper healthcare infrastructure and professionals is limited, making it difficult to provide holistic care to pregnant women and their children. However, AI technologies such as digital chatbots and support groups can aid in maternal and neonatal health monitoring and management. These technologies can engage users in follow-up questions about their health in their desired language, helping to disperse basic health information.
Figure 1: Focus Areas on Role of AI in complimenting maternal health
Challenges and Solutions for AI
Explainable Artificial Intelligence (XAI) or Dependable AI (DAI) can provide insights into the decision-making process of AI models. This level of explainability increases the confidence that medical practitioners and AI researchers have in the system, leading to broader adoption of AI in the healthcare field. By understanding why someone has been classified as ill or otherwise, the perception of AI models as a “black box” can be changed, making them more scalable and employable. XAI can be merged with smart healthcare systems that incorporate the Internet of Things, cloud computing, and AI, particularly in the fields of maternal and neonatal health. These intelligent healthcare systems can be utilized for various purposes, including disease diagnosis and treatment selection.
In some crucial small sample size healthcare problems where large datasets are not available, Few-shot learning or Zero-shot learning can be used to train AI models. These learning frameworks utilize domain information to reach medical decisions or predictions, making them efficient tools for doctors to handle rare medical conditions and problems that require years of experience.
Conclusion
Improving maternal and newborn health requires bringing speedy diagnosis and treatment to point-of-care settings in developing nations with limited resources.
🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?
Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.
Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.
🌟 How can personalized medicine transform breast cancer treatment in Spain?
The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.
Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.
🌟 Are we on the brink of transforming breast cancer treatment?
NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.
Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.